Long-Term Debt (Annual)

Long-Term Debt: The sum of all long term debt fields.

NervGen Pharma Corp. (NGEN) Long-Term Debt data is not available.

Quarterly Annual

Figures for fiscal year ending 2025-12-31

Income Statement Financials
Revenue	--
Net Income	--
Cost of Goods Sold	--
Gross Profit	--
Operating Expenses	--
Operating Income	--
Non-Operating Income/Expense	--
Pre-Tax Income	--
Normalized Pre-Tax Income	--
Income after Taxes	--
Income from Continuous Operations	--
Consolidated Net Income/Loss	--
Normalized Income after Taxes	--
EBIT	--
EBITDA	--
Weighted-Average Shares Outstanding (Basic)	--
Weighted-Average Shares Outstanding (Diluted)	--
Earnings per Share (EPS) (Basic)	--
Earnings per Share (EPS) (Diluted)	--
Balance Sheet Financials
Current Assets	--
Property, Plant, and Equipment	--
Long-Term Assets	--
Total Assets	0.00M
Current Liabilities	--
Long-Term Debt	--
Long-Term Liabilities	--
Total Liabilities	--
Common Equity	--
Tangible Shareholders Equity	--
Shareholders Equity	--
Common Shares Outstanding	--
Cash Flow Statement Financials
Cash Flow from Operating Activities	--
Cash Flow from Investing Activities	--
Cash Flow from Financial Activities	--
Beginning Cash	--
End Cash	--
Increase/Decrease in Cash	--
Stock-Based Compensation	--
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	--
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	--
Debt to Equity Ratio	--
Gross Margin	--
Operating Margin	--
EBIT Margin	--
EBITDA Margin	--
Pre-Tax Profit Margin	--
Profit Margin	--
Free Cash Flow	--
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	--
Inventory Turnover	--
Receiveable Turnover	--
Days Sales in Receivables	--
Return on Equity	--
Return on Tangible Equity	--
Return on Assets	--
Return on Investments	--
Book Value Per Share	--
Free Cash Flow per Share	--
Operating Cash Flow per Share	--

Data from Zacks Investment Research, Inc.